An Eight Component Decision-Making Model for Problem Gambling:A Systems Approach to Stimulate Integrative Research

Journal of Gambling Studies

Volumn 27, Issue 4, 2011, Pages 523-563

  Nussbaum, David ^a,b   Honarmand, Kimia ^c   Govoni, Richard ^d   Kalahani Bargis, Martina ^a   Bass, Stephanie ^a   Ni, Xinqun ^e   LaForge, Kaitlyn ^f   Burden, Andrea ^a   Romero, Kristoffer ^a   Basarke, Sonya ^g   Courbasson, Christine ^e   Deamond, Wade ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b ONTARIO SHORES CENTRE FOR MENTAL HEALTH SCIENCES   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF WINDSOR   (Canada)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f BROCK UNIVERSITY   (Canada)

^g RYERSON UNIVERSITY   (Canada)

^h Yorkville University   (Canada)

Author keywords

Decision making; Impulse control disorders; Impulsivity; Problem gambling; Psychopharmacology

Indexed keywords

ADDICTION; BEHAVIOR; CLASSIFICATION; CONTROL; DECISION MAKING; FEMALE; HIGH RISK BEHAVIOR; HUMAN; MALE; PATHOLOGICAL GAMBLING; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL MODEL; REPRODUCIBILITY; REVIEW; SELF CONCEPT; SOCIAL BEHAVIOR;

BEHAVIOR, ADDICTIVE; DECISION MAKING; FEMALE; GAMBLING; HUMANS; INTERNAL-EXTERNAL CONTROL; MALE; MODELS, PSYCHOLOGICAL; POWER (PSYCHOLOGY); REPRODUCIBILITY OF RESULTS; RISK-TAKING; SELF CONCEPT; SELF EFFICACY; SOCIAL BEHAVIOR;

EID: 81155139134     PISSN: 10505350     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10899-010-9219-8     Document Type: Review

References (139)

1. Abler, B., Hahlbrock, R., Unrath, A., Groen, G., & Kassubek, J. (2009). At-risk for pathological gambling: Imaging neural reward processing under chronic dopamine agonists. Brain, 132(9), 2396-2402.
2. Adekunle, A. G., Fedoroff, P., Firestone, P., Bradford, J., & Curry, S. (2006). Serum testosterone, luteinizing hormone, hostility and recidivism in convicted sex offenders. Biological Psychiatry, 59, 128S.
3. Alexander, G. E., DeLong, M., & Strick, P. E. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience, 9, 357-381.
4. Alexander, J. K., Hillier, A., Smith, R. M., Tivarus, M. E., & Bersdarf, D. Q. (2007). Beta-adrenergic modulation of cognitive flexibility during stress. Journal of Cognitive Neuroscience, 19, 468-478.
5. APA (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, D. C.: American Psychiatric Association.
6. Assadi, S. M., Yucel, M., & Pantelis, C. (2009). Dopamine modulates neural networks involved in effort-based decision-making. Neuroscience and Biobehavioral Reviews, 33, 383-393.
7. Bass, S. L. S., & Nussbaum, D. (2010). Decision-making and aggression in forensic psychiatric inpatients. Criminal Justice and Behavior, 37, 365-383.
8. Bechara, A., Damasio, H., & Damasio, A. R. (2001). Manipulation of dopamine and serotonin cause different effects on covert and overt decision-making. Society for Neuroscience Abstracts, 27.
9. Bechara, A., Damasio, A. R., Damasio, H., & Anderson, S. W. (1994). Insensitivity to future consequences following damage to human prefrontal cortex. Cognition, 50, 7-15.
10. Bechara, A., Dolan, S., & Hindes, A. (2002). Decision-making and addiction (Part II): Myopia for the future or hypersensitivity to reward? Neuropsychologia, 40, 1690-1705.
11. Bergh, C., Eklund, T., Sodersten, P., & Nordin, C. (1997). Altered dopamine function in pathological gambling. Psychological Medicine, 27, 473-475.
12. Black, D. W., Shaw, M. C., & Allen, J. (2008). Extended release carbamazepine the treatment of pathological gambling: An open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32(5), 1191-1194.
13. Blanco, C., Báñez, A., Blanco-Jerez, C. R., Baca-Garcia, E., & Sáiz-Ruiz, J. (2001). Plasma testosterone and pathological gambling. Psychiatry Research, 105, 117-121.
14. Blanco, C., Orensanz-Munoz, L., Blanco-Jerez, C., & Saiz-Ruiz, J. (1996). Pathological gambling and platelet MAO activity: A psychobiological study. American Journal of Psychiatry, 153, 119-121.
15. Blanco, C., Petkova, E., Ibanez, A., & Saiz-Ruiz, J. (2002). A pilot placebo-controlled study of fluvoxamine for pathological gambling. Annals of Clinical Psychiatry, 14, 9-15.
16. Blaszczynski, A. P., Winter, S. W., & McConaghy, N. (1986). Plasma endorphin levels in pathological gambling. Journal of Gambling Behavior, 2, 3-14.
17. Blazszczynski, A., & Nower, L. (2002). A pathways model of problem and pathological gambling. Addiction, 97, 487-499.
18. Blazszczynski, A., & Steel, Z. (1998). Personality disorders among pathological gamblers. Journal of Gambling Studies, 14, 51-75.
19. Blazszczynski, A., Steel, Z., & McConaghy, N. (1997). Impulsivity in problem gamblers: The antisocial impulsivist. Addictions, 92, 75-87.
20. B agonists in the treatment of psychostimulant addiction. Alcohol and Alcoholism, 37, 478-484.
21. Brunner, D., & Hen, R. (1997). Insights into the neurobiology of impulsive behavior from serotonin receptor knockout mice. Annals of the New York Academy of Sciences, 836, 81-105.
22. Capraro, R. M. (2004). Statistical significance, effect size reporting, and confidence intervals: Best reporting strategies. Journal for Research in Mathematics Education, 35, 57-62.
23. Carrasco, J. L., Saiz-Ruiz, J., Hollander, E., Cesar, J., & Lopez-Ibor, J. J., Jr. (1994). Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatrica et Neurologica Scandinavica, 90, 427-431.
24. Cavedini, P., Riboldi, G., Keller, R., D'Annucci, A., & Bellodi, L. (2002). Frontal lobe dysfunction in pathological gambling patients. Biological Psychiatry, 51(4), 334-341.
25. Comings, D. E. (1998). Why different rules are required for polygenic inheritance: Lessons from studies of the DRD2 gene. Alcohol, 16, 61-70.
26. Comings, D. E., Dietz, G., Johnson, J. P., & MacMurray, J. P. (1999). Association of the enkephalinase gene with low amplitude P300 waves. Neuroreport: For Rapid Communication of Neuroscience Research, 10, 2283-2285.
27. Comings, D. E., Gade-Andavolu, R., Gonzalez, N., Wu, S., Muhleman, D., Chen, C., et al. (2001). The addictive effects of neurotransmitter genes in pathological gambling. Clinical Genetics, 60, 107-116.
28. Comings, D. E., Muhleman, D., & Gysin, R. (1996). Dopamine D-sub-2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: A study and replication. Biological Psychiatry, 40, 368-372.
29. Cox, B. J., Yu, N., Afifi, A. O., & Ladouceur, R. (2005). A national survey of gambling problems in Canada. Canadian Journal of Psychiatry, 50, 213-217.
30. Cunningham-Williams, R. M., Abdallah, A. B., Callahan, C., & Cottler, L. (2007). Problem gambling and violence among community-recruited female substance abusers. Psychological of Addictive Behaviors, 21(2), 239-243.
31. Da Silva Lobo, D. S., Vallada, H. P., Knight, J., Martins, S. S., Tavares, H., Gentil, V., et al. (2007). Dopamine genes and pathological gambling in discordant sib-pairs. Journal of Gambling Studies, 23, 421-433.
32. Dabbs, J. M., & Dabbs, M. G. (2000). Heroes, rogues, and lovers. Testosterone and behavior. New York: McGraw Hill.
33. Dannon, P. N., Lowengrub, K., Gonopolski, Y., Musin, E., & Kotler, M. (2005a). Topiramate versus fluvoxamine in the treatment of pathological gambling: A randomized, blind-rater comparison study. Clinical Neuropharmacology, 28(1), 6-10.
34. Dannon, P. N., Lowengrub, K., Musin, E., Gonopolski, Y., & Kotler, M. (2005b). Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: A preliminary blind-rater study. Journal of Clinical Psychopharmacology, 25(6), 593-596.
35. Daw, N. D., Kakade, S., & Dayan, P. (2002). Opponent interactions between serotonin and dopamine. Neural Networks, 15, 603-616.
36. de Castro, P. I., Ibanez, A., Saiz-Ruiz, J., & Fernandez-Piqueras, J. (2001). Concurrent positive association between pathological gambling and functional DNA polymorphisms at the MAO-A and the 5-HT transporter genes. Molecular Psychiatry, 7, 927-928.
37. DeCaria, C. M., Hollander, E., Grossman, R., Wong, C. M., Mosovich, S. A., & Cherkasky, S. (1996). Diagnosis, neurobiology, and treatment of pathological gambling. Journal of Clinical Psychiatry, 57, 80-83.
38. DeCaria, C. M., Hollander, E., Nora, R., Stein, D., Simeon, D., & Cohen, I. (1997). Gambling: Biological/genetic, treatment, government, and gambling concerns: Neurobiology and treatment of pathological gambling. Paper presented at the American Psychiatric Association Annual Meeting, San Diego, CA.
39. Devilly, G. J. (2005). ClinTools Software for Windows. Version 4 (Computer Program). Swinburne University, Australia: The Centre for Neuropsychology.
40. Durlak, J. A. (1995). Understanding meta-analysis. In L. G. Grimm & P. R. Yarnold (Eds.), Reading and understanding multivariate statistics. Washington, D. C.: APA.
41. Elliot, A. J., Faler, J., McGregor, H. A., Campbell, W. K., Sedikides, C., & Harackiewicz, J. M. (2000). Competence valuation as a strategic intrinsic motivation process. Personality and Social Psychology Bulletin, 26, 780-794.
42. Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196, 129-136.
43. Fahlke, C., Lorenz, J. G., Long, J., Champouz, M., Suomi, S. J., & Higley, J. D. (2000). Rearing experiences and stress-induced plasma cortisol as early risk factors for excessive alcohol consumption in nonhuman primates. Alcoholism, Clinical and Experimental Research, 24, 644-650.
44. Fennema, H., & van Assen, M. (1998). Measuring the utility of losses by means of the tradeoff method. Journal of Risk and Uncertainty, 17, 277-295.
45. Fong, T., Kalechstein, A., Bernhard, B., et al. (2008). A double-blind, placebo controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacology, Biochemistry and Behavior, 89, 298-303.
46. Franklin, T. R., Acton, P. D., Maldijian, J. A., Gray, J. D., Croft, J. R., Dackis, C. A., et al. (2002). Decreased gray matter concentration in the insular, orbitofrontal, cingulate, temporal cortices of cocaine patients. Biological Psychiatry, 51, 134-142.
47. Ghebrial, M. E. (2006). Hormone-behavior correlates among male and female psychopathic participants: Relationship to Gray's model of behavioural inhibition and activation systems. Dissertation Abstracts International: Section B: The Sciences and Engineering, 66(12-B), 6921.
48. Gianoulakis, C., De Waele, J., & Thavundayil, J. (1996). Implication of the endogenous opioid system in excessive ethanol consumption. Alcohol, 13, 19-23.
49. Giladi, N., Weitzman, N., Schreiber, S., Shabtai, H., & Peretz, C. (2007). New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: The role of dopamine agonist treatment and age at motor symptoms onset. Journal of Psychopharmacology, 21, 501-506.
50. Goudriaan, A. E., Oosterlaan, J., de Beurs, E., & van den Brink, W. (2004). Pathological gambling: A comprehensive review of biobehavioural findings. Neuroscience & Behavioral Reviews, 28, 123-141.
51. Goudriaan, A. E., Oosterlaan, J., de Beurs, E., & van den Brink, W. (2005). Decision making in pathological gambling: A comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls. Cognitive Brain Research. Special Issue: Multiple Perspectives on Decision Making, 23, 137-151.
52. Grant, J. E., & Kim, S. W. (2006). Medication management of pathological gambling. Minnesota Medicine, 89, 44-48.
53. Grant, J. E., Kim, S. W., & Odlaug, B. L. (2007). N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study. Biological Psychiatry, 62, 652-657.
54. Grant, J. E., Kim, S. W., Potenza, M. N., et al. (2003). Paroxetine treatment of pathological gambling: A multi-center randomized controlled trial. International Clinical Psychopharmacology, 18, 243-249.
55. Grant, J. E., & Potenza, M. N. (2006). Escitalopram treatment of pathological gambling with co-occurring anxiety: An open-label pilot study with double-blind continuation. International Clinical Psychopharmacology, 21(4), 203-209.
56. Grant, J. E., Potenza, M. N., Hollander, E., Cunningham-Williams, R., Nurminen, T., Smits, G., & Kallio, A. (2006). Multicenter investigation of the opiod antagonist nalmefene in the treatment of pathological gambling. American Journal of Psychiatry, 163, 303-312.
57. Griffiths, M. D., & Delfabbro, P. H. (2001). The biopsychosocial approach to the study of gambling. Gambling: The Electronic Journal of Gambling Issues, 5, 1-33.
58. Hanson, R. K., Bourgnon, G., Helmus, L., & Hodgson, S. (2009). The principles of effective correctional treatment also apply to sexual offenders: A meta-analysis. Criminal Justice and Behavior, 36, 865-891.
59. Hollander, E., DeCaria, C. M., Finkell, J. N., Begaz, T., Wong, C. M., & Cartwright, C. A. (2000). Randomized double blind fluvoxamine/placebo crossover trial in pathological gambling. Biological Psychiatry, 47, 813-817.
60. Hollander, E., DeCaria, C. M., Mari, E., Wong, C. M., Mosovich, S., Grossman, R., et al. (1998). Short-term single-blind fluvoxamine treatment of pathological gambling. American Journal of Psychiatry, 155, 1781-1783.
61. Holman, A. J. (2009). Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. Journal of Gambling Studies, 25(3), 425-431.
62. Ibanez, A., de Castro, P., Fernandez-Piqueras, J., & Saiz-Ruiz, J. (2000). Association between the low-functional MAO-A gene promoter and pathological gambling. Versailles (France): Eighth World Congress on Psychiatric Genetics.
63. Ibanez, A., de Castro, P. I., Fernandez-Piqueras, J., & Saiz-Ruiz, J. (2001). Tyrosine hydroxylase gene and pathological gambling: An association study. 7th World Congress of Psychiatric Genetics, Monterey, CA(USA), p. 272.
64. Johansson, A., Grant, J., Kim, S. W., Odlaug, B. L., & Götestam, K. G. (2009). Risk factors for problematic gambling: A critical literature review. Journal of Gambling Studies, 25(1), 67-92.
65. Kalivas, P. W. (2009). The glutamate homeostasis theory of addiction. Nature Neuroscience Reviews, 10, 561-572.
66. Kalivas, P. W., & Volkow, N. D. (2005). The neural basis of addiction: A pathology of motivation and choice. American Journal of Psychiatry, 162, 1403-1413.
67. Kaufman, K. R., Kugler, S. L., & Sachdeo, R. C. (2002). Tiagabine in the management of postencephalitic epilepsy and impulse control disorder. Epilepsy & Behavior, 3, 190-194.
68. Kerfoot, E. C., Chattillion, E. A., & Williams, C. L. (2008). Functional interactions between the nucleus tractus solitaries (NTS) and nucleus accumbens shell in modulating memory for arousing experiences. Neurobiology of Learning and Memory, 89, 47-60.
69. Kessler, R. C., Hwang, I., LaBrie, R., Petukhova, M., Sampson, N. A., Winters, K. C., et al. (2008). DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychological Medicine, 38, 1351-1360.
70. Kim, S. W., & Grant, J. E. (2001). An open naltrexone treatment study in pathological gambling disorder. International Clinical Psychopharmacology, 16, 285-289.
71. Kim, S. W., Grant, J. E., Adson, D. E., & Shin, Y. C. (2001). Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological Psychiatry, 49, 914-921.
72. Kim, S. W., Grant, J. E., Adson, D. E., Shin, Y. C., & Zaninelli, R. (2002). A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. Journal of Clinical Psychiatry, 63, 501-507.
73. Kreek, M. J., Nielsen, D. A., Butelman, E. R., & LaForge, K. S. (2005). Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nature Neuroscience, 8, 1450-1457.
74. Krystal, J. H., D'Souza, C., Mathalon, D., Perry, E., Aysenil, B., & Hoffman, R. (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology, 169, 215.
75. Lee, T. K., La Brie, R. A., Grant, J. E., Kim, S. W., & Shaffer, H. J. (2008). The structure of pathological gambling among Korean gamblers: A cluster and factor analysis of clinical and demographic characteristics. International Journal of Mental Health Addiction, 6, 551-563.
76. McClure, S. M., Laibson, D. L., Loewnstein, G., & Cohen, J. D. (2004). Separate neural systems value immediate and delayed monetary reward. Science, 306, 503-507.
77. McElroy, S., Nelson, E., Welge, J., et al. (2008). Olanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial. Journal of Clinical Psychiatry, 69, 433-440.
78. Meyer, G., Hauffa, B. P., Schedlowski, M., Pawlak, C., Stadler, M. A., & Exton, M. S. (2000). Biological Psychiatry, 48, 948-953.
79. Meyer, G., Schwertfeger, J., Exton, M. S., Janssen, O. E., Knapp, W., Stadler, M. A., Schedlowski, M., & Kruger, T. H. C. (2004). Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology, 29, 1272-1280.
80. Moreno, I., Saiz-Ruiz, J., & Lopez Ibor, J. J. (1991). Serotonin and gambling dependence. Human Psychopharmacology, 6, S9-S12.
81. Nelson, S. E., Gebauer, L., LaBrie, R. A., & Shaffer, H. J. (2009). Gambling problems symptom patterns and stability across individual and timeframe. Psychology of Addictive Behaviors, 23(3), 523-533.
82. Nordin, C., & Eklundh, T. (1999). CSF 5-HIAA disposition in pathologic male gamblers. CNS Spectrums, 4, 25-33.
83. Nordin, C., & Sjodin, I. (2006). CSF monoamine patterns in pathological gamblers and healthy controls. Journal of Psychiatric Research, 40, 454-459.
84. Nower, L., & Blazszczynski, A. (2006). Impulsivity and pathological gambling: A descriptive model. International Gambling Studies, 6(1), 61-75.
85. Olausson, P., Jentsch, J. D., Krueger, D. D., Tronson, N. C., Nairn, A. C., & Taylor, J. R. (2007). Orbitofrontal cortex and cognitive-motivational impairments in psychostimulant addiction. Annals of the New York Academy of Sciences, 1121, 610-638.
86. Pallanti, S., Baldini Rossi, N., Sood, E., & Hollander, E. (2002a). Nefazodone treatment of pathological gambling: A prospective open-label controlled trial. Journal of Clinical Psychiatry, 63, 1034-1039.
87. Pallanti, S., Bernardi, S., Quercioli, L., DeCaria, C., & Hollander, E. (2006). Serotonin dysfunction in pathological gamblers: Increased prolactin response to oral m-CPP versus placebo. CNS Spectrums, 11, 956-964.
88. Pallanti, S., Quercioli, L., Sood, E., & Hollander, E. (2002b). Lithium and valproate treatment of pathological gambling: A randomized single-blind study. Journal of Clinical Psychiatry, 63(7), 559-564.
89. Perez, D. C. I., Ibanez, A., Saiz-Ruiz, J., & Fernandez-Piqueras, J. (1999). Genetic contribution to pathological gambling: Possible association between a functional DNA polymorphism at the serotonin transporter gene (5-HTT) and affected men. Pharmacogenetics, 9, 397-400.
90. Petry, N. M. (2001). Substance abuse, pathological gambling, and impulsiveness. Drug and Alcohol Dependence, 63(1), 29-38.
91. Petry, N. M., & Oncken, C. (2002). Cigarette smoking is associated with increased severity of gambling problems in treatment-seeking gamblers. Addiction, 97(6), 745-753.
92. Pirastu, R., Fais, R., Messina, M., Bini, V., Spiga, S., Falconieri, D., et al. (2006). Impaired decision-making in opiate-dependent subjects: Effect of pharmacological therapies. Drug and Alcohol Dependence, 83, 163-168.
93. Potenza, M. N. (2008). The neurobiology of pathological gambling and drug addiction: An overview and new findings. Philosophical Transactions of the Royal Society B: Biological Sciences, 363, 1507.
94. Potenza, M. N. (2009). Non-substance and substance addictions. Addiction, 104, 1016-1017.
95. Potenza, M. N., Leung, H. C., Blumberg, H. P., Peterson, B. S., Fulbright, R. K., Lacadie, C. M., et al. (2003a). An fMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. The American Journal of Psychiatry, 160(11), 1990-1994.
96. Potenza, M. N., Steinberg, M. A., Skudlarski, P., Fulbright, R. K., Lacadie, C. M., Wilber, M. K., et al. (2003b). Gambling urges in pathological gambling: A functional magnetic resonance imaging study. Archives of General Psychiatry, 60, 828-836.
97. Reuter, J., Raedler, T., Rose, M., Hand, I., Glascher, J., & Buchel, C. (2005). Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nature Neuroscience, 8, 147-148.
98. Rogers, R. D., Blackshaw, A. J., Middleton, H. C., Matthews, K., Hawtin, K., Crowley, C., et al. (1999). Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: Implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology. Special Issue: Impulsivity, 146, 482-491.
99. Rogers, R. D., Lancaster, M., Wakeley, J., & Bhagwagar, Z. (2004). Effects of beta-adrenoceptor blockade on components of human decision-making. Psychopharmacology, 172, 157-164.
100. Rompre, P. P., & Wise, R. A. (1989). Behavioral evidence for midbrain dopamine depolarization inactivation. Brain Research, 477, 152-156.
101. A receptors modulate dopamine release from rat striatal synaptosomes. Journal of Neurochemistry, 61, 1634-1639.
102. Ross, S., & Peselow, E. (2009). The neurobiology of addictive disorders. Clinical Neuropharmacology, 32, 269-276.
103. Roussos, P., Giakoumaki, S. G., Pavlakis, S., & Bitsios, P. (2008). Planning, decision-making and the COMT rs4818 polymorphism in healthy males. Neuropsychologia, 46, 757-763.
104. Roy, A., Adinoff, B., Roehrich, L., Lamparski, D., Custer, R., Lorenz, V., et al. (1988). Pathological gambling: A psychobiological study. Archives of General Psychiatry, 45, 369-373.
105. Saiz-Ruiz, J., Blanco, C., Ibanez, A., Masramon, X., Gomez, M. M., Madrigal, M., et al. (2005). Sertraline treatment of pathological gambling: A pilot study. Journal of Clinical Psychiatry, 66, 28-33.
106. Scherrer, J. F., Xian, H., Kapp, J. M. K., Waterman, B., Shah, K. R., Volberg, R., et al. (2007). Association between exposure to childhood and lifetime traumatic events and lifetime traumatic pathological gambling in a twin cohort. Journal of Nervous and Mental Disease, 95, 72-78.
107. Schmitt, L. H., Harrison, G. A., & Spargo, R. M. (1998). Variation in epinephrine and cortisol excretion rates associated with behavior in an Australian Aboriginal community. American Journal of Physical Anthropology, 106, 249-253.
108. Sharpe, L. (2004). Patterns of autonomic arousal in imaginal situations of winning and losing in problem gambling. Journal of Gambling Studies, 20, 95-104.
109. Shead, N. W., & Hodgins, D. C. (2009). Affect-regulation expectancies among gamblers. Journal of Gambling Studies, 25(3), 357-375.
110. Shima, K., & Tanji, J. (1998). Role of cingulate motor area cells in voluntary movement selection based on reward. Science, 282, 5392.
111. Shinohara, K., Yanagisawa, A., Kagota, Y., Gomi, A., Nemoto, K., Moriya, E., et al. (1999). Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate. Applied Human Science: Journal of Physiological Anthropology, 18, 37-42.
112. Skitch, S. A., & Hodgins, D. C. (2004). Impulsivity, compulsivity and pathological gambling: An exploratory study of pathological gambling as an impulsivity-compulsivity spectrum disorder. International Gambling Studies, 4(2), 175-188.
113. Sofuoglu, M., Poling, J., Gonzalez, G., Gonsai, K., & Kosten, T. (2006). Cocaine withdrawal symptoms predict medication response in cocaine users. American Journal of Drug and Alcohol Abuse, 32, 617-627.
114. Stahl, S. M. (2008). Essential psychopharmacology: Neuroscientific basis and practical applications (3rd ed.). New York: Cambridge University Press.
115. Steeves, T. D. L., Miyasaki, J., Zurowski, M., Lang, A. E., Pellecchia, G., van Eimeren, T., et al. (2009). Increased striatal dopamine release in Parkinsonian patients with pathological gambling: A [11C] raclopride PET study. Brain, 132(5), 1376-1385.
116. Stewart, S. H., & Zack, M. (2008). Development and psychometric evaluation of a three-dimensional Gambling Motives Questionnaire. Addiction, 103, 1110-1117.
117. Stewart, S. H., Zack, M., Collins, P., Klein, R., & Fragopoulos, F. (2008). Subtyping pathological gamblers ion the basis of affective motivations for gambling: Relations to gambling problems, drinking problems, and affective motivation for drinking. Psychology of Addictive Behaviors, 22(2), 257-268.
118. Tanabe, J., Thompson, L., Claus, E., Dalwani, M., Hutchison, K., & Banich, M. T. (2007). Prefrontal cortex activity is reduced in gambling and non-gambling substance users during decision-making. Human Brain Mapping, 28, 1276-1286.
119. Terburg, D., Mogan, B., & van Honk, J. (2009). The testosterone-cortisol ratio: A hormonal marker for proneness to social aggression. International Journal of Law and Psychiatry, 32, 216-223.
120. Thanos, P. K., Michaelides, M., Umegaki, H., & Volkow, N. D. (2008). D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. Synapse, 62, 481-486.
121. Thiel, A., Hilker, R., Kessler, J., Habedank, B., Herholz, K., & Heiss, W. D. (2003). Activation of basal ganglia loops in idiopathic Parkinson's disease: A PET study. Journal of Neural Transmission, 110, 1303-1311.
122. Thompson, M., & Thompson, L. (2003). The Neurofeedback book: An introduction to basic concepts in applied psychophysiology (1st ed.). Colorado: The Association for Applied Psychophysiology and Biofeedback.
123. Toneatto, T. (1999). Cognitive psychopathology of problem gambling. Substance Use and Misuse, 34, 1593-1604.
124. Topf, J. L., Yip, S. W., & Potenza, M. N. (2009). Pathologic gambling: Biological and clinical considerations. Journal of Addiction Medicine, 3, 111-119.
125. Toplak, M. E., Liu, E., MacPherson, R., Toneatto, T., & Stanovich, K. E. (2007). The reasoning skills and thinking dispositions of problem gamblers: A dual-process taxonomy. Journal of Behavioral Decision Making, 20, 103-124.
126. van Hank, J., Schutter, D. J. L. G., Hermans, E. J., & Putman, P. (2003). Low cortisol levels and the balance between punishment sensitivity and reward dependency. Neuroreport, 14, 1993-1996.
127. van Honk, J., Schutter, D. J. L. G., Hermans, E. J., Putman, P., Tuiten, A., & Koppeschaar, H. (2004). Testosterone shifts the balance between sensitivity for punishment and reward in healthy young women. Psychoneuroendocrinology, 29, 937-943.
128. Vogel-Sprott, M. (1967). Alcohol effects on human behavior under reward and punishment. Psychopharmacologia, 11, 337-344.
129. Vogel-Sprott, M., Easdon, C., Fillmore, M., Finn, P., & Justus, A. (2001). Alcohol and behavioral control: Cognitive and neural mechanisms. Alcoholism, Clinical and Experimental Research, 25, 117-121.
130. Volkow, N. D., Wang, G. J., & Telang, F. (2007). Profound decrease in dopamine release in striatum in detoxified alcoholics: Possible orbitofrontal involvement. Journal of Neuroscience, 27, 12700-12706.
131. Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., et al. (2006). Association of dopamine agonist use with impulse control disorders in Parkinson disease. Archives of Neurology, 63(7), 969-973.
132. Westphal, J. R. (2008). Pathological gambling: Psychiatric models. International Journal of Mental Health Addiction, 6, 602-618.
133. Wilkinson, L., & Task Force on Statistical Inference. (1999). Statistical methods in psychology journals: Guidelines and explanations. American Psychologist, 54, 594-604.
134. Williams, R. J., West, B. L., & Simpson, R. I. (2007). Prevention of problem gambling. In G. Smith, D. C. Hodgins, & R. J. Williams (Eds.), Research and measurement issues in gambling studies (pp. 400-425). Burlington: Academic Press.
135. Winstanley, C. A., Theobald, D. E. H., Dalley, J. W., Cardinal, R. N., & Robin, T. W. (2006). Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal and orbitofrontal cortex during a test of impulsive choice. Cerebral Cortex, 16, 106-114.
136. Wong, D. F., Kuwabara, H., Schretlen, D. J., Bonson, K. R., Zhou, Y., Nandi, A., et al. (2006). Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology, 31(12), 2716-2727.
137. Zack, M., & Poulos, C. X. (2004). Amphetamine primes motivation to gamble and gamblingrelated semantic networks in problem gamblers. Neuropsychopharmacology, 29, 195-207.
138. Zack, M., & Poulos, C. X. (2007). A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neurospsychopharmacology, 32, 1678-1686.
139. Zimmerman, M., Breen, R. B., & Posternak, M. A. (2002). An open-label study of citalopram in the treatment of pathological gambling. Journal of Clinical Psychiatry, 63, 44-48.